Source / episode info
- **Episode:**443
- **Title:**Divine Intervention Episode 443: The Clutch Acetylcholinesterase Inhibitor Podcast (for Step 1-3)
- **Published:**2023-02-21
- Source:Episode page
One-liner
This episode provides a comprehensive review of acetylcholinesterase inhibitors, detailing their four functional groups, mechanisms of action, and critical clinical applications ranging from treating Alzheimer's disease and Myasthenia Gravis to managing cholinergic crises and reversing neuromuscular blockade.
High-yield summary
- Mechanism: AChEIs are indirect cholinergic agents that inhibit the enzyme acetylcholine esterase (AChE), leading to increased synaptic levels of acetylcholine (ACh).
- Four Groups: The USMLE framework divides AChEIs into: 1) Organophosphates/Nerve Agents (toxins); 2) Alzheimer's agents (Donepezil, Rivastigmine, Galantamine); 3) Peripheral quaternary inhibitors (Pyridostigmine, Neostigmine); and 4) BBB-crossing drugs (Phizostigmine).
- Cholinergic Crisis: Caused by excessive ACh (e.g., organophosphate poisoning), presenting with SLUDGE/DUMBBEL symptoms (Salivation, Lacrimation, Urination, Diarrhea, GI upset, Emesis; Miosis, Bradycardia, Bronchospasm, etc.). Treatment involves Atropine (muscarinic antagonist) and Pralidoxime (reactivates OP-inhibited AChE).
- Contraindications: Never use AChEIs in the setting of high-grade GI or urinary obstruction (risk of rupture due to excessive peristalsis/detrusor contraction), COPD, or severe asthma (risk of bronchospasm).
- Key Distinction: For reversing atropine toxicity, a drug that crosses the blood-brain barrier (Phizostigmine) is required to treat central muscarinic effects.
Learning objectives
- Differentiate between the four functional classes of acetylcholinesterase inhibitors (AChEIs) based on their mechanism and BBB permeability.
- Recognize the clinical presentation and appropriate antidotal therapy for cholinergic crisis due to organophosphate poisoning.
- Select the correct AChEI for specific conditions, such as Myasthenia Gravis or Alzheimer's disease, while avoiding inappropriate agents (e.g., Pyridostigmine for AD).
- Identify critical contraindications for using AChEIs in acute settings (e.g., high-grade obstruction, COPD exacerbation, heart block).
- Understand the pathophysiology of cholinergic excess and its reversal with muscarinic antagonists like Atropine.
Board exam buzzwords